犹他州医疗委员会要求暂停人工智能处方更新计划, Utah medical board seeks suspension of AI prescription renewal program due to safety concerns.

犹他州的医疗委员会呼吁暂停该州首个 AI 的处方更新计划,理由是患者安全问题和缺乏医学监督. Utah’s medical board is calling for the suspension of the state’s first-of-its-kind AI prescription renewal program, citing patient safety concerns and a lack of medical oversight. 董事会认为,处方更新需要经过许可的专业人员评估患者病情并监测药物相互作用, 他们说人工智能无法执行这一任务. The board argues that prescription renewals require licensed professionals to assess patient conditions and monitor for drug interactions, a task they say AI cannot perform. 虽然董事会支持在医疗保健领域探索人工智能, 但他们坚持认为医学专业人员必须在实施之前审查此类举措. While the board supports exploring AI in healthcare, they insist medical professionals must review such initiatives before implementation.